Distribution of MTB among newly diagnosed HIV patients at Malindi District Hospital during July 2012 to June 2013. Sheldon kalu 1 1 Malindi District Hospital.

Slides:



Advertisements
Similar presentations
ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
Advertisements

Your name Institution/organization Meeting Date. Introduction.
Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.
Implementation of Diagnostics in Resource-Limited Settings Amy Piatek Global Health Bureau, Office of Health, Infectious Diseases & Nutrition U.S. Agency.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
World Health Organization TB Case Definitions
Nucleic Acid Amplification Test for Tuberculosis
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and Rifampin Resistance in HIV Infected & HIV uninfected Pulmonary TB suspects: ACTG.
Module 11: Clinical guide to Xpert MTB/RIF Global Laboratory Initiative – Xpert MTB/RIF Training Package.
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
KEY CHANGES IN THE NEW NTBLCP GUIDELINES
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs Using the Compendium to Plan for Monitoring and Evaluation of NTPs.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
World Tuberculosis Day 2014 The TB situation in 2012: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
MDR and XDR TB Bruce A. Bush, M.D. Regional Tuberculosis Consultant
Tuberculosis Presented by Vivian Pham and Vivian Nguyen.
Module 10: Understanding Laboratory Data *Image courtesy of: World Lung Foundation.
Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.
Module 1: Overview of tuberculosis (TB) and TB diagnostics Global Laboratory Initiative – Xpert MTB/RIF Training Package.
Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,
MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor.
TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
A decentralized model of care for drug-resistant tuberculosis in a high HIV prevalence setting Cheryl McDermid, Helen Cox, Simiso Sokhela, Gilles van Cutsem,
Tuberculosis burden in households of patients with multi drug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study.
Outcomes among patients treated for tuberculosis in Limpopo Province, South Africa, Mmakgotso Pilane, Lazarus Kuonza, Eric Maimela.
Tuberculosis Research of INA-RESPOND on Drug-resistant
Max O’Donnell, Nesri Padayatchi, Iqubal Master, Garth Osburn, Robert Horsburgh Treatment of Extensively Drug Resistant Tuberculosis Among Patients with.
Components of HIV/AIDS Case Surveillance: Case Report Forms and Sources.
Progress of the Singapore TB Elimination Programme (STEP)
6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,
TB/HIV management survey  Baseline audit in parallel with guidelines development process  Survey of clinician opinion and practice  Data collection.
Module 2 - Epidemiology of Tuberculosis
PREVALENCE OF MDR-TB AMONGST PATIENTS WITH HIV AND TB CO- INFECTION SEEN AT THE DOTS CLINIC OF N.I.M.R., LAGOS, NIGERIA. Enya V.N.V, Onubogu C.C., Wahab.
Revision of new diagnostics for TB
International Health Policy Program -Thailand Policy decision on multi drug resistant(MDR), extreme drug resistant(XDR) tuberculosis screening: How it.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Beyond Sputum Cups and Four Drugs The Responsibility of the Practicing Clinician in the Community Control of Tuberculosis V. R. Koppaka, MD, PhD Division.
High cost of Xpert MTB/RIF ® testing per tuberculosis case diagnosed at Partners in Hope Medical Center, a public private HIV care clinic in Lilongwe,
Washington D.C., USA, July 2012www.aids2012.org Implementing Xpert ® MTB/RIF in Rural Zimbabwe Impact on diagnosis of smear-negative TB and time-
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Molecular diagnosis of drug resistant tuberculosis by a DNA array
Integration of TB and HIV Screening, Care and Treatment in Mulago Hospital, Uganda Rhoda Wanyenze, Doris Mwesigire, Henry Luzze, Violet Gwokyalya, Julius.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
Dr Justin O’Grady. Zambia is a high burden TB and high HIV setting 44,154 TB cases notified in 2010 – incidence of 462/100,000 pop Approx 48% of pulmonary.
MULTIDRUG- RESISTANT TUBERCULOSIS (MDR-TB) by Dr Mat Zuki Mat Jaeb 1.
TB AND HIV/AIDS THE SITUATION AT BMC Care & Treatment Unit CME, 5/5/20166 PRESENTERS: Dr. Desideris Bernard, Dr. Magawa.
Bacteriophage based test for the rapid detection & Antibiotic sensitivity test of TB Viro102: Bacteriophages & Phage Therapy 3 Credit hours NUST Centre.
The 16 th International Conference on AIDS & STIs in Africa, Addis Ababa Trends in HIV Seroprevalence among clients with newly diagnosed tuberculosis in.
Measures to Decrease TB Prevalence in the Barents Region Andrey O. Maryandyshev Elena I. Nikishova Dmitry V. Perkhin.
Roundtable. Detection and treatment of TB Andrew Black.
Peter Cegielski, MD, MPH Team Leader for Prevention, Care and Treatment Global Tuberculosis Branch Division of Global HIV and TB Reinforcing the Surveillance.
PMDT IN CHINESE TAIPEI ECONOMY Anita Pei-Chun Chan, MD, PhD Medical Officer, TCDC Associated Director, TB Research Center, TCDC Assistant Professor, Institute.
Notified AIDS and HIV Infection Cases in the Seychelles: Epidemiological Trends Ministry of Health, SeychellesMinistry of Health, Seychelles –N. E. Udonwa.
World Tuberculosis Day 2016 Monitoring the implementation of the Framework Action Plan to Fight Tuberculosis in the European Union – Situation in 2014.
Article review Rapid Molecular Detection of Tuberculosis and Rifampin Resistance [MTB-RIF test] Catharina C. Boehme, M.D., Pamela Nabeta, M.D., Doris Hillemann,
Treatment of TB Disease
Daniel Meressa, M.D. Global Health Committee St. Peter’s Hospital
Field Testing of OMNI-gene TB Sputum Optimizer in Malawi
World Tuberculosis Day 2014
Daffodil International University (DIU), Dhaka Bangladesh
Nucleic Acid Amplification Test for Tuberculosis
PAEDIATRIC TUBERCULOSIS MAY STILL BE UNDER DIAGNOSED AND UNDER TREATED
بسم الله الرحمن الرحيم.
Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries Kathrin Zürcher, Marie Ballif, Lukas Fenner, Sonia.
World Tuberculosis Day 2016
World Tuberculosis Day 2014
Goal Objectives Expected Outcomes
Deciphering TB Lab Reports
Presentation transcript:

Distribution of MTB among newly diagnosed HIV patients at Malindi District Hospital during July 2012 to June Sheldon kalu 1 1 Malindi District Hospital ABSTRACT Objective: To establish the distribution of MTB Rifampicin resistance in newly diagnosed HIV patients at Malindi District Hospital. Background: TB is a major cause of death among people living with HIV with Sub-Saharan Africa bearing the brunt of the HIV fuelled TB epidemic. Method: Xpert MTB/RIF Assay was used to analyse sputum samples from each patient for detection of MTB and Rifampicin resistance. Results: 88 males were positive for MTB (35% of total males) with 5(5.68% of total positive males) Rifampicin resistant. October had highest males tested with 56, March, with 5 patients, was the lowest. 21 males were averagely tested each month with mean positives of 7. Males had negative Chitest of with positive Chitest of A total of 42 females (22% of total females) were positive with 1Rifampicin resistant (1.14% of total positive females). October had highest females-58 tested while March lowest, had 2. On average, 16 females were tested each month with mean positive of 4. Female negative chitest was while positive chitest was Conclusion: Infection with MTB and Rifampicin resistant MTB strains were found in the newly diagnosed HIV patients. Key words:MTB- Mycobacterium tuberculosis bacilli,PCR- Polymerase Chain Reaction, Resistance,HIV.

ACKNOWLEDGEMENT Entire Laboratory Team – Malindi District Hospital Malindi District Hospital Management DEDICATION All HIV/TB infected individuals

INTRODUCTION BACKGROUND OF THE STUDY Justification: Kenya is one of the 22 high TB burden countries and is ranked 13 th according to the WHO Global Tuberculosis Report And the management cost of TB is increasingly becoming expensive with the increase in TB co-infection with HIV.WHO Global Tuberculosis Report 2010 Malindi District Hospital has 250 beds. It enjoys a maternity shelter for pregnant women, Maternal Child Health Care department with pediatrics ward, CCC (HIV and Aids wing which also constitutes counseling and testing area). Given the distance from other centers for health facilities such as Garrisa and Kilifi, the hospital receives a lot of patients both for inpatient and outpatient. The District Laboratory is net worked for CD4 & Gene Xpert with Lamu District, Tana Delta District, Tana River District & Kilifi District. Objective: To establish the distribution of MTB and Rifampicin resistance strains of MTB in newly diagnosed HIV patients at Malindi District Hospital.

Literature Review Globally, around 2 billion people are infected with M. tuberculosis 1. Every year almost 9 million people develop active disease and 2 million people lose their lives to the illness. Active tuberculosis is predominantly pulmonary in nature. The route of transmission of pulmonary TB is through the air, which makes this a highly transmissible disease. Given the infectious nature of pulmonary TB, fast and accurate diagnosis is an important element of TB treatment and control. Treatment involves prolonged administration of multiple drugs and is usually highly effective. However, M. tuberculosis strains may become resistant to one or more of the drugs, making cure much more difficult to achieve. Four common first-line drugs used in antituberculosis therapy are Isoniazid (INH), Rifampicin (also known as Rifampin, RIF), Ethambutol (EMB), and Pyrazinimide (PZA). As documented by WHO, RIF resistance is rarely encountered by itself, and usually indicates resistance to a number of other anti-TB drugs 2. It is most commonly seen in multi-drug resistant (MDR-TB) strains and has a reported frequency of greater than 95% in such isolates 3, 4, 5. MDR-TB is defined as a tuberculous disease caused by a bacterial strain that is resistant to at least INH and RIF. Resistance to RIF or other first-line drugs usually indicates the need for full susceptibility testing, including testing against second-line agents. Molecular detection of TB and rpoB gene mutations associated with RIF resistance greatly speeds the diagnosis of both drug-susceptible and MDR tuberculosis. With the Xpert MTB/RIF test, this can be accomplished in fresh sputum samples and in prepared sediments in less than 2 hours. The rapid detection of MTB and RIF resistance allows the physician to make critical patient management decisions regarding therapy during the same medical encounter.

MATERIALS AND METHOD Permission to carry out the retrospective study was sought from the Malindi District Hospital Laboratory Manager and the Hospital Administration and approval given by the Hospital Ethical Committee and DTLC. The Kenya’s Ministry of Health National Leprosy and Tuberculosis Programme Lab Register for AFB together with the genexpert register were used to tally the total number of Newly diagnosed HIV TB suspects and the positive sputum smears counted against total smears for the respective newly diagnosed HIV patients during the study period. Quality Control Each test includes a Sample Processing Control (SPC) and probe check (PCC). Sample Processing Control (SPC)—Ensures the sample was correctly processed. The SPC contains non-infectious spores in the form of a dry spore cake that is included in each cartridge to verify adequate processing of MTB. The SPC verifies that lysis of MTB has occurred if the organisms are present and verifies that specimen processing is adequate. Additionally, this control detects specimen associated inhibition of the real-time PCR assay. The SPC should be positive in a negative sample and can be negative or positive in a positive sample. The SPC passes if it meets the validated acceptance criteria. The test result will be “Invalid” if the SPC is not detected in a negative test. Probe Check Control (PCC)—Before the start of the PCR reaction, the GeneXpert Dx System measures the fluorescence signal from the probes to monitor bead rehydration, reaction-tube filling, probe integrity and dye stability. Probe Check passes if it meets the assigned acceptance criteria.

DATA MANAGEMENT AND ANALYSIS: The data collected was recorded in a form then later transferred to Microsoft Excel statistical package for analysis guided by gender. The results was then presented in charts, tables and graphs. RESULTS 35% and 22% males and females respectively had MTB detected

monthmalefemale Jul247 Aug3014 Sep910 Oct5658 Nov4943 Dec93 Jan82 Feb1815 Mar57 Apr2318 May119 Jun115 COMMENTS: MONTH WITH HIGHEST MALE/FEMALE TURN OUT – OCTOBER MONTH WITH LOWEST MALE TURN OUT – MARCH

monthly distribution of MTB/RIF Resistance occurrencegenderJulAugSepOctNovDecJanFebMarAprMayJun total male female grand total MTB detected male female RIF Resistance male female

Monthly gender distribution of MTB detection occurrencemtb gendermalefemale Jul81 Aug80 Sep34 Oct2215 Nov1512 Dec30 Jan41 Feb54 Mar21 Apr80 May81 Jun23 Total8842 minimum20 maximum2215 mean74

CONCLUSION Newly diagnosed HIV patients have MTB the infectious agent responsible for TB disease with males at high risk than their female counterparts. Rifampicin resistance strain of MTB was confirmed among positive MTB patients with HIV infection

References 1. WHO report Anti-tuberculosis resistance in the world: fourth global report. WHO/HTM/TB/ Morris SL, Bai Gh, Suffys P, Portillo-Gomez L, Fairchok M, Rouse D. Molecular mechanisms of multidrug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis 1995; 171: Ashok Rattan, Awdhesh Kalia, and Nishat Ahmad, Multidrug-Resistant Mycobacterium tuberculosis: Molecular Perspectives, Emerging Infectious Diseases, Vol.4 No.2, 5. Francis J. Curry National Tuberculosis Center and California Department of Public Health, 2008: Drug-Resistant Tuberculosis, A Survival Guide for Clinicians, Second Edition. McKinney RW (eds) (1993). HHS Publication number (CDC) Clinical and Laboratory Standards Institute (formerly National Committee for Clinical Laboratory Standards). Protection of laboratory workers from occupationally acquired infections; Approved Guideline. Document M29 (refer to latest edition). 8. Kent PT, Kubica GP Public Health Mycobacteriology—A Guide for Level III Laboratory, Centers of Disease Control, Atlanta, Publication no. PB Laboratory Services in Tuberculosis Control: Part II, Microscopy WHO/TB/98.258; p 1-61.